Bioartificial devices and cellular matrices therefor

• US 5,824,331 A
• Filed: 12/07/1995
• Issued: 10/20/1998
• Est. Priority Date: 02/24/1992
• Status: Expired due to Term

• Current Assignee: Encelle, Inc. (Surgalign Holdings, Inc.)
• Original Assignee: Encelle, Inc. (Surgalign Holdings, Inc.)
• Inventors: Usala, Anton-Lewis
• Primary Examiner(s): AZPURU, CARLOS A
• Application Number:
  US08/568,503
• Time in Patent Office: 1,048 Days
• Field of Search: 424/423, 424/424, 435/1.1, 435/182, 623/11, 514/772.3
• US Class Current: 424/424
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0231 Chemically defined matrices, e.g. alginate gels, for immobilising, holding or storing cells, tissue or organs for preservation purposes; Chemically altering or fixing cells, tissue or organs, e.g. by cross-linking, for preservation purposes
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61F 2310/00365 Proteins; Polypeptides; Degradation products thereof
• CPC Class Codes: A61K 2035/126 Immunoprotecting barriers, e.g. jackets, diffusion chambers
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 27/222 Gelatin
• CPC Class Codes: A61L 27/24 Collagen
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: C12N 2500/05 Inorganic components
• CPC Class Codes: C12N 2500/32 Amino acids
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/30 Synthetic polymers thermoreactive polymers, e.g. PNIPAm, C12N2539/10
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 2533/70 Polysaccharides
• CPC Class Codes: C12N 5/0012 Cell encapsulation
• CPC Class Codes: C12N 5/0677 Three-dimensional culture, tissue culture or organ culture; Encapsulated cells

Abstract

A device for the effective release of cellular moieties, including hormones, wherein a matrix containing a hormone producing cellular moiety is encapsulated with a nonimmunogenic polymeric material of poly-para-xylylene or other aromatic based polymeric moiety having a membrane portion with a porosity blocking passage therethrough of immunogenic agents and permitting passage therethrough of effective nutrients for said cellular moiety and the hormone produced thereby, an improved matrix for the storage, manufacture, functional testing, and viral infection testing of cellular moieties wherein a collagen based hydrogel is processed to present a liquid phase at host temperature and functions as a substrate for cellular attachment with additives effective for limiting thermal and pressure trauma, and an improved method for the harvesting tissue from organs.

Claims

1. An improved storage matrix for prolonging the functional survival of cellular tissue, comprising:

denatured collagen and intact collagen for providing binding sites for said tissue in an amount of about 0.01 to 30 mM;

a liquid in a n amount of about 15 to 96.5 percent by weight;

a polymeric buffer substrate for reducing cellular damage to said islets at said storage temperature in an amount of about 0.01 to 1000 micromolar, wherein said substrate forms a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent passage of immunogenic agents.

2. The matrix as recited in claim 1 wherein said polymeric buffer substrate is a long chain carbohydrate based polymer sugar.

3. The matrix as recited in claim 2 wherein said polymeric buffer substrate is dextran.

4. The matrix as recited in claim 1 wherein said polymeric substrate is amylopectin.

5. The matrix as recited in claim 1 wherein said polymeric substrate is a polymeric proteoglycan.

6. The matrix as recited in claim 1 wherein said nitric oxide inhibitor is a sulfanated moiety protecting protecting the tissue from hypoxic, chemical, thermal, or mechanical trauma.

7. The matrix as recited in claim 6 wherein said nitric oxide savenger is selected from the group comprising dextran, heparin, cysteine, and cystine.

8. The matrix as recited in claim 7 wherein said nitric oxide inhibitor is an L-arginine analog.

9. The matrix as recited in claim 8 wherein said l-arginine analog is selected from the group comprising aminoguanidine, N-monoethyl L-arginine, N-nitro-L-arginine, or D-arginine functioning to replace L-arginine as a substrate for nitric oxide formation.

10. A hydrogel matrix suitable for long term storage of cellular tissue comprising from about 15 to 96.5 percent by weight of an aqueous nutrient solution containing

0.001 to 100 mM collagen

0.01 to 1000 micromolar cryoprotectant

0.001 to 100 mM divalent chelator

0.01 micromolar to 300 mM nitric oxide inhibitor.

11. The matrix of claim 10 wherein the collagen is a denatured collagen.

12. The matrix of claim 10 wherein the coliagen is a combination of denatured collagen and native collagen.

13. The matrix of claim 10 wherein the cryoprotectant i s a long chain carbohydrate based sugar.

14. The matrix of claim 10 wherein the cryoprotectant is selected from the group consisting of dextran, sulfated dextran, anylopectin and proteoglycan.

15. The matrix of claim 10 wherein the nitric oxide inhibitor is an amino acid.

16. The matrix of claim 10 wherein the nitric oxide inhibitor is selected from the group consisting of dextran, heparin, cysteine and cystine.

17. The matrix of claim 10 wherein the nitric oxide inhibitor is an L-arginine analog.

18. The matrix of claim 17 wherein said L-arginine analog is selected from the group consisting of aminoguanidine, N-monoethyl L-arginine and N-nitro-L-arginine.

19. The matrix of claim 10 wherein the divalent chelator is selected from the group consisting of citrate, EDTA and EGTA.

20. The matrix of claim 10 wherein the nutrient solution includes a water soluble protein.

21. The matrix of claim 10 additionally comprising an antibiotic.

22. The hydrogel matrix of claim 10 characterized in that said matrix is a solid at 4°

C. and a liquid at 37°

C.

23. A storage matrix for prolonging the functional survival of cellular tissue comprising collagen in an amount sufficient to provide a structural rigidity, water, and a polymeric buffer to provide a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent passage of immunogenic agents.

24. The matrix of claim 23, wherein said collagen is a denatured collagen.

25. The matrix of claim 23, wherein said collagen is a combination of denatured collagen and native collagen.

26. The matrix of claim 23, further comprising a divalent chelator.

27. The matrix of claim 25, further comprising a nitric oxide inhibitor.

28. The matrix of claim 26, further comprising a nitric oxide inhibitor.

29. The matrix of claim 25, further comprising a cryoprotectant.

30. The matrix of claim 28, further comprising a cryoprotectant.

31. The matrix of claim 30, wherein said cryoprotectant is a long chain carbohydrate-based sugar.

32. The matrix of claim 31, wherein said cryoprotectant is selected from the group consisting of dextran, sulfated dextran, amylopectin and proteoglycan.

33. The matrix of claim 28, wherein said nitric oxide inhibitor is an amino acid.

34. The matrix of claim 28, wherein said nitric oxide inhibitor is selected from the group consisting of dextran, heparin, cysteine and cystine.

35. The matrix of claim 33, wherein said nitric oxide inhibitor is an L-arginine analog.

36. The matrix of claim 35, wherein said L-arginine analog is selected from thc group consisting of aminoguanidine, N-monoethyl L-arginine, and N-nitro-L-arginine.

37. The matrix of claim 26, wherein said divalent chelator is selected from the group consisting of citrate, EDTA, and EGTA.

38. The matrix of claim 23, further comprising an antibiotic.

39. A method for prolonging the functional survival of cellular tissue, said method comprising placing said tissue in a storage matrix comprising a combination of denatured collagen and native collagen in an amount sufficient to provide a structural rigidity, and a polymeric buffer to provide a membrane coating having a porosity to permit passage of nutrients and biological agents and prevent the passage of immunogenic agents.

40. The method of claim 39, wherein said matrix further comprises a divalent chelator.

41. The method of claim 40, wherein said matrix further comprises a nitric oxide inhibitor.

42. The method of claim 41, wherein said matrix further comprises a cryoprotectant.

43. The method of claim 40, wherein said matrix further comprises a cryoprotectant.

44. The method of claim 43, wherein said cryoprotectant is a long chain carbohydrate-based sugar.

45. The method of claim 43, wherein said cryoprotectant is selected from the group consisting of dextran, sulfated dextran, amylopectin and proteoglycan.

46. The method of claim 41, wherein said nitric oxide inhibitor is an amino acid.

47. The method of claim 41, wherein said nitric oxide inhibitor is selected from the group consisting of dextran, heparin, cysteine and cystine.

48. The method of claim 46, wherein said nitric oxide inhibitor is an L-arginine analog.

49. The method of claim 48, wherein said L-arginine analog is selected from the group consisting of aminoguanidine, N-monoethyl L-arginine, and N-nitro-L-arginine.

50. The method of claim 40, wherein said divalent chelator is selected from the group consisting of citrate, EDTA, and EGTA.

51. The method of claim 39, wherein said matrix further comprises an antibiotic.